false
OasisLMS
ar,zh-CN,zh-TW,en,fr,de,hi,it,ja,es,ur
Catalog
Secondary Prevention for Atherosclerotic Cardiovas ...
Addressing Gaps in ASCVD Care: SCAI Secondary Prev ...
Addressing Gaps in ASCVD Care: SCAI Secondary Prevention Toolkit
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The video discusses the 2018 guidelines and individual evidence for non-statin therapy for high-risk patients. It mentions that for patients with established cardiovascular disease but not at high risk, starting high-intensity statin therapy to lower LDL cholesterol by 50% is recommended. For patients over 75 years old already taking statin therapy, continuation of high-intensity or moderate-intensity statin is reasonable. Patients with very high risk should be on high-intensity statin or maximally tolerated statin. The video also discusses follow-up and monitoring of statin therapy, non-statin therapies for statin-intolerant patients, and the use of statins in women of childbearing age. It also mentions the use of ezetimibe, bempedoic acid, and PCSK9 inhibitors as alternative therapies. These therapies have been shown to effectively reduce LDL cholesterol and cardiovascular events in various patient populations.
Asset Subtitle
Debabrata Mukherjee, MD, FSCAI
Keywords
2018 guidelines
non-statin therapy
LDL cholesterol
statin therapy
cardiovascular events
×